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1The use of oral anticoagulant (OAC) therapy for stroke prevention in atrial fibrillation (AF) has been trans-
formed by the availability of the nonvitamin K antagonist 
oral anticoagulants (NOACs) which show relative efficacy, 
safety, and convenient alternatives to the vitamin K antago-
nists (eg, warfarin).1,2 Currently, 4 NOACs are available for 
clinical use, namely the direct thrombin inhibitor, dabiga-
tran; and the oral factor Xa inhibitors, rivaroxaban, apixaban, 
and edoxaban. The numbers of postmarketing observational 
real-world studies (RWS) have largely reflected the sequence 
these drugs have been introduced to the market.3 Compared 
with clinical trials, the RWS have less selected cohorts, help-
ing to understand the effect of NOACs in specific clinical sce-
narios or conditions.3
Prior RWS have analyzed and been pooled together for dab-
igatran and rivaroxaban, broadly confirming the results from 
their respective phase III clinical trials.4,5
Our aim was to perform a systematic review and meta-anal-
ysis of all observational RWS comparing apixaban with other 
available OAC drugs (warfarin, dabigatran, rivaroxaban, and 
edoxaban).
Methods
To perform this systematic review and meta-analysis, the following 
criteria for studies selection were considered: (1) observational stud-
ies focusing on patients with established AF; (2) studies reporting 
data on patients with AF prescribed with OAC, comparing data about 
patients treated with apixaban and warfarin, dabigatran, rivaroxaban, 
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2  Stroke  January 2018
or edoxaban and their impact on major adverse events on follow-up 
observation; (3) At least 100 patients, with 50 patients taking apixa-
ban or a relevant subgroup of apixaban treated patients; (4) At least 
3 months of follow-up. Exclusion criteria were as follows: (1) con-
ference abstracts, letters, comments, case reports, and editorials; (2) 
studies not published in English. No explicit protocol was drafted to 
perform the systematic review. The systematic review and meta-anal-
ysis were performed according to PRISMA recommendations (http://
www.prisma-statement.org/). The data that support the findings of 
this study are available from the corresponding author on reasonable 
request.
Search Strategy
A comprehensive literature search was performed using PubMed 
and Scopus databases up to 6 March, 2017. Search terms included 
atrial fibrillation, apixaban, dabigatran, rivaroxaban, and edoxaban. 
The electronic search was performed for peer-reviewed journals, 
and, if applicable, some further additional references were gathered 
from searches through bibliographies of identified papers and from 
authors’ personal knowledge.
All details about studies selection, data extraction, outcomes defi-
nition, as well as on bias assessment,6 and statistical analysis have 
been reported in the online-only Data Supplement. All statistical 
analyses were undertaken using Review Manager (RevMan) version 
5.3 (The Cochrane Collaboration 2014, Nordic Cochrane Centre, 
Copenhagen, Denmark).
Results
The original literature search retrieved a total of 9680 results 
from Pubmed and Scopus databases (Figure 1). After the 
selection process (Figure 1), a total of 173 studies underwent 
full-text assessment. After the exclusion of 158 papers and the 
after addition of 2 papers, based on authors knowledge, a total 
of 16 studies7–22 were included in the systematic review and 
the final meta-analysis (Table).
Study Characteristics
Overall, a total of 170 814 patients treated with apixaban were 
included in the 16 studies. Of these, 2 studies were published in 
2015,8,9 7 studies were published in 2016,10–16 and 7 studies were 
published in 2017.7,17–22 Three of 16 studies were single-cen-
ter cohort studies,8–10 6 studies were retrieved from insurance 
databases, 1 study was a regional database,7 and 6 studies were 
taken from nationwide registries.12,15,18–20,22 Eight studies were 
based in Europe while 6 studies were based in United States, 1 
study was based in the Middle-East, and 1 study in Japan.
Mean/median age was consistent among most of the studies, 
ranging from 70 to 76 years; 1 study enrolled slightly younger 
patients, mean (SD) age 68.5 (12.4) years13 while another study 
enrolled significantly older patients, mean (SD) age 83.9 (8.2) 
years.22 Four studies enrolling patients with a high thromboem-
bolic risk (CHA2DS2-VASc score ≥4 [congestive heart failure, 
hypertension, age ≥75 years, diabetes mellitus, stroke/transient 
ischemic attack, vascular disease, age 65–74 years, sex cate-
gory]).14,16,17,22 Eight studies compared apixaban with warfarin, 
dabigatran, and rivaroxaban8,9,12,13,15,19,20,22; 4 studies compared 
Figure 1. Flow-chart of studies’ selection 
process.
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Proietti et al  Apixaban in Real-World Studies on AF  3
apixaban directly only with warfarin7,11,16,21; and 4 studies com-
pared apixaban with both dabigatran and rivaroxaban.10,14,17,18 
No studies were retrieved comparing apixaban with edoxaban.
Data about use of reduced dose were available for 10 
out of 16 studies.7,9,11,13–16,19–21 The lowest proportion of the 
reduced dose was 13.5%13 whereas the highest proportion 
reported was 37.8%20; of note, 5 of 10 studies reported a 
proportion of reduced dose of >25%.7,9,15,19,20 One study 
comprised only patients prescribed with NOACs reduced 
dose.22
Table. Selected Studies for Systematic Review and Meta-Analysis
Study Year Study Cohort Location n*
Reduced 
Dose
Age 
(Mean)
CHA
2
DS
2
-
VASc (Mean) Comparator(s) Main Outcomes FU (Mean)
Lee et al8
2015
Single-
center 
cohort
United 
Kingdom
53 NA 74 3 (median)
Warfarin, 
dabigatran, 
rivaroxaban
CVE, any bleeding, 
all-cause death, OAC 
switching
0.92 y
Shiga et al9
2015
Single-
center 
cohort
Japan 102 36 (35.3%) 70 NA
Warfarin, 
dabigatran, 
rivaroxaban
Discontinuation, TE, 
major bleeding
1.83–2 y
Al-Khalili 
et al10 2016
Single-
center 
cohort
Sweden 251 NA 73 3 (median)
Dabigatran, 
rivaroxaban
Any bleeding, 
discontinuation, TE, all-
cause death
0.95–1.18 y
Coleman 
et al11
2016
Insurance 
database
United 
States
4332 671 (15.5%) 71 3.47 Warfarin ICH, ischemic stroke 0.48–0.52 y
Larsen 
et al12 2016
Nationwide 
registries
Denmark 6349 0 71.3 2.8
Warfarin, 
dabigatran, 
rivaroxaban
Stroke/SE, ischemic 
stroke, all-cause death
1.9 y
Lip et al13
2016
Insurance 
database
United 
States
7438 1002 (13.5%) 68.5 2.8
Warfarin, 
dabigatran, 
rivaroxaban (PSM 
comparison)
Major bleeding 0.40–0.48 y
Noseworthy 
et al14 2016
Insurance 
database
United 
States
6565 1201 (18.3%)
73 
(median)
4 (median)
Dabigatran, 
rivaroxaban (PSM 
comparison)
Stroke/SE, major 
bleeding
NA
Staerk 
et al15 2016
Nationwide 
registries
Denmark 6899 2547 (36.9%)
76 
(median)
3.11
Warfarin, 
dabigatran, 
rivaroxaban
Stroke/SE, ICH 0.56–1.06 y
Yao et al16
2016
Insurance 
database
United 
States
7698 1393 (18.1%)
73 
(median)
4 (median) Warfarin
Stroke/SE, major 
bleeding
0.50 y
Abraham 
et al17 2017
Insurance 
database
United 
States
6576 NA 72.3 4.0
Dabigatran, 
rivaroxaban (PSM 
comparison)
GI bleed NA
Altay et al18
2017
Nationwide 
registry
Turkey 625 NA 70.3 NA
Dabigatran, 
rivaroxaban
TE, any bleeding 0.9 y
Forslund 
et al7 2017
Regional 
registry
Sweden 3587 1126 (31.4%) 75 3.69 Warfarin
Any stroke/IS/TIA, major 
bleeding, all-cause 
death
1.07–1.61 y
Halvorsen 
et al19 2017
Nationwide 
registries
Norway 6506 1901 (29.2%) 74.5 2.93
Warfarin, 
dabigatran, 
rivaroxaban
Major/CRNM bleeding 0.39–0.58 y
Lamberts 
et al20 2017
Nationwide 
registries
Denmark 7963 3010 (37.8%) 75.4 3 (median)
Warfarin, 
Dabigatran, 
rivaroxaban
Major bleeding, 
persistence
0.73–1.4 y
Li et al21
2017
Insurance 
database
United 
States
38 470 6568 (17.1%) 70.9 3.2
Warfarin (PSM 
comparison)
Stroke/SE, major 
bleeding
0.55 y
Nielsen 
et al22
2017
Nationwide 
registries
Denmark 4400 100% 83.9 4.3
Warfarin, 
dabigatran, 
rivaroxaban
Stroke/SE, IS, 
hemorrhagic stroke, 
major bleeding, GI 
bleeding, any bleeding
2.3 y
CRNM indicates clinically relevant nonmajor; CVE, cerebrovascular events; FU, follow-up; GI, gastrointestinal; ICH, intracranial hemorrhage; IS, ischemic stroke; 
NA, not available; OAC, oral anticoagulant; PSM, propensity score matching; SE, systemic embolism; TE, thromboembolic events; and TIA, transient ischemic attach.
*Number of patients is referred to number of patients treated with apixaban.
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Study Results
In most of the studies comparing apixaban with warfarin, 
apixaban was associated with a lower risk for stroke and sys-
temic embolic events, as well as for major bleeding, particu-
larly intracranial hemorrhage (ICH).11,16,21 Only in the study 
by Forslund et al,7 no difference was found between apixaban 
and warfarin.
Overall, the studies that compared apixaban with dabi-
gatran and rivaroxaban found that apixaban was broadly 
comparable with dabigatran in terms of stroke/systemic 
embolic events with unclear differences compared with 
rivaroxaban.10,14,18 Conversely, apixaban demonstrated a 
significant lower risk for major bleeding events.10,14,17,18 In 
the study by Abraham et al,17 the lower risk of gastrointes-
tinal bleeding (GIB) with apixaban was independent of age 
strata.
Risk of Bias Evaluation
A bias evaluation was performed (Table I in the online-only 
Data Supplement). Overall, most studies reported a low risk 
of bias (11 studies) while 3 studies10,12,22 had a moderate risk 
of bias and 2 studies8,18 had a high risk of bias. We did not find 
significant publication bias in the main primary outcomes, 
for comparisons between apixaban, warfarin, and dabigatran 
(Figures I and II in the online-only Data Supplement) while 
a small effect could be detected for rivaroxaban, particularly 
for the any thromboembolic event outcome (Figure III in the 
online-only Data Supplement) and similarly for dabigatran, 
particularly for the major bleeding outcome (Figure IIB in the 
online-only Data Supplement).
Meta-Analysis of Selected Studies
Apixaban Versus Warfarin
When comparing apixaban and warfarin, there was overall 
no significant difference in any thromboembolic events (odds 
ratio [OR], 0.92; 95% confidence interval [CI], 0.71–1.17; 
Figure 2A). In the regular dose group, there was a significant 
reduction in risk of any thromboembolic event (OR, 0.77; 
95% CI, 0.64–0.93); conversely, the reduced dose subgroup 
had a significant 27% relative risk increase in any thromboem-
bolic event (P<0.0001 for subgroup differences).
For stroke, no significant difference was found between 
apixaban and warfarin, both in the regular and reduced dose 
subgroups (Figure 2B). Conversely, hemorrhagic stroke risk 
was significantly reduced in apixaban treated patients (36% 
relative risk reduction [RRR]; P=0.0003), especially for 
the regular dose group (Figure IV in the online-only Data 
Supplement).
Compared with warfarin, major bleeding risk was signifi-
cantly lower for patients treated with apixaban (OR, 0.62; 
95% CI, 0.51–0.75), with consistency for regular and low dose 
subgroups (Figure 2C). Risk reduction with apixaban was 
even greater when considering ICH (46% RRR; P<0.00001) 
or GIB (OR, 0.63; 95% CI, 0.57–0.70; P<0.00001) compared 
with warfarin (Figure V in the online-only Data Supplement). 
The risk for any bleeding was also lower in apixaban patients 
(P=0.009; Figure VI in the online-only Data Supplement).
Given the extremely high level of heterogeneity, we did 
not perform meta-analysis for occurrence of all-cause death. 
Currently, only a limited number of RWS reported on all-
cause death risks comparing apixaban and warfarin (Figure 
Figure 2. Efficacy and safety of apixaban vs warfarin. A, Any thromboembolic events; (B) stroke; (C) major bleeding; and (D) intracranial 
hemorrhage. CI indicates confidence interval.
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VII in the online-only Data Supplement). These studies 
reported varying results with 1 study suggesting a significant 
protection for apixaban, 1 study suggesting no difference, and 
1 study indicating a higher risk for apixaban even though it 
compared warfarin with apixaban reduced dose.
Number of events for Forslund et al7 were retrieved from haz-
ard ratios (see Methods in the online-only Data Supplement). 
A sensitivity analysis excluding that study showed superim-
posable results (data not shown).
Apixaban Versus Dabigatran
Overall, there were nonsignificant differences between 
apixaban and dabigatran in risk of any thromboembolic 
event (P=0.30) although a lower risk was found in apixaban 
patients prescribed with the reduced dose (OR, 0.86; 95% CI, 
0.75–0.99; Figure 3A). No difference was seen for stroke risk 
(Figure 3B).
Major bleeding risk was significantly lower in apixa-
ban patients compared with dabigatran ones (35% RRR; 
P<0.00001) even though only 1 study was included in the 
reduced dose subgroup (Figure 3C). Although no difference 
was found for ICH (Figure 3D), patients prescribed apixaban 
had a significantly lower risk for GIB (57% RRR; P<0.00001) 
and any bleeding (31% RRR; P<0.00001; Figures VIII and IX 
in the online-only Data Supplement). No difference was found 
in all-cause death between apixaban and dabigatran (Figure X 
in the online-only Data Supplement).
Number of events for Noseworthy et al14 were retrieved 
from hazard ratios (see Methods in the online-only Data 
Supplement). A sensitivity analysis excluding that study 
showed superimposable results (data not shown).
Apixaban Versus Rivaroxaban
Compared with apixaban, there was a significant superior-
ity for rivaroxaban for any thromboembolic event (OR, 1.27; 
95% CI, 1.13–1.43) and stroke (OR, 1.31; 95% CI, 1.15–1.50), 
mainly driven by the treatment effect found in the reduced 
dose subgroup (Figure 4A and 4B). No difference was found 
for hemorrhagic stroke occurrence although few studies were 
available for evaluation (Figure XI in the online-only Data 
Supplement).
The risk of major bleeding was significantly lower in 
patients treated with apixaban compared with rivaroxaban 
(46% RRR; P<0.00001), consistent with doses subgroups 
(Figure 4C). There was a significant risk reduction in ICH 
(OR, 0.46; 95% CI, 0.25–0.85; Figure 4D) and GIB for apix-
aban compared with rivaroxaban (64% RRR; P<0.00001; 
Figure XII in the online-only Data Supplement), as well as for 
any bleeding (OR, 0.56; 95% CI, 0.50–0.61; Figure XIII in the 
online-only Data Supplement) There was a significant reduc-
tion for all-cause death with apixaban compared with rivarox-
aban with the regular dose subgroup (50% RRR; P<0.00001; 
Figure XIV in the online-only Data Supplement).
Number of events for Noseworthy et al14 were retrieved 
from hazard ratios (see Methods in the online-only Data 
Supplement). A sensitivity analysis excluding that study 
showed superimposable results (data not shown).
Bias-Stratified Sensitivity Analysis
A sensitivity analysis was performed, grouping studies accord-
ing to risk of bias verifying all the outcomes for which a sig-
nificant treatment effect was found, either for apixaban or any 
of the comparators. No significant differences were found for 
Figure 3. Efficacy and safety of apixaban vs dabigatran. A, Any thromboembolic events; (B) stroke; (C) major bleeding; and (D) intracra-
nial hemorrhage. CI indicates confidence interval.
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6  Stroke  January 2018
most of the outcomes analyzed (data not shown). For the com-
parison of apixaban versus warfarin for any thromboembolic 
event, bias-stratified analysis found a 25% RRR (P<0.00001) 
when considering only low risk of bias studies (Figure XV 
in the online-only Data Supplement ). The risk reduction for 
any thromboembolic event occurrence with rivaroxaban was 
driven by the moderate/high risk of bias studies (OR, 1.38; 
95% CI, 1.19–1.59) while no significant difference was 
found for the low risk of bias subgroup (OR, 1.10; 95% CI, 
0.89–1.35; Figure XVI in the online-only Data Supplement). 
Similar findings were seen for stroke occurrence (Figure XVII 
in the online-only Data Supplement).
Absolute Risk Reductions and Number-
Needed to Treat Compared With Warfarin
To assess the effectiveness of apixaban compared with warfa-
rin in RWS, we estimated absolute risk reduction (ARR) and 
number-needed to treat (NNT). Compared with warfarin, apix-
aban resulted in a similar effect reducing any thromboembolic 
event (ARR: 0.23%), with a slightly better effectiveness in 
reducing risk of stroke (ARR: 0.48%). Comparing RWS data 
with the ARISTOTLE trial (Apixaban for Reduction in Stroke 
and Other Thromboembolic Events in Atrial Fibrillation),23 
apixaban allowed a consistently higher NNT for any thrombo-
embolic event while a similar clinical effectiveness was found 
for stroke events (Figure 5).
For major bleeding events, an ARR of 1.41% resulting in 
an NNT of 71, similar to ARISTOTLE. For ICH, a 2.7-fold 
increase in NNT was seen compared with ARISTOTLE (345 
versus 128) because of an ARR of 0.29% (Figure 5). Similarly, 
with an ARR of 0.57% for GIB, a 1.8-fold increase in NNT 
was observed in RWS compared with ARISTOTLE. Despite 
an ARR of 1.67% in all-cause death, the NNT was lower in 
RWS than in the ARISTOTLE trial.
Discussion
Our systematic review and meta-analysis show that use of 
apixaban in real-life is associated with an overall nonsignifi-
cant difference in stroke and any thromboembolic events when 
compared with warfarin. A better safety profile was demon-
strated when comparing apixaban use to warfarin, dabigatran, 
or rivaroxaban.
Compared with the phase III ARISTOTLE trial,23 RWS data 
showed that apixaban seems to have a similar effectiveness than 
warfarin in reducing any thromboembolic event occurrence, as 
seen in the randomized clinical trial context, with a slightly 
better effect for stroke event occurrence. Moreover, apixaban 
was as effective as dabigatran and rivaroxaban in reducing the 
risk of thromboembolic events. Importantly, apixaban was 
found to be safer than warfarin in reducing major bleeding, 
particularly ICH and GIB. Also, apixaban was safer than both 
dabigatran and rivaroxaban in reducing bleeding events. Data 
on mortality reduction were inconclusive in our analysis.
Since their introduction in daily practice, NOACs have 
been increasingly used, contributing to the increase in OAC 
uptake seen in several studies,24–26 even though treatment 
gaps still remain.27 NOACs are currently recommended over 
vitamin K antagonists in most of the international guide-
lines.28–30 Nevertheless, many patients eligible for use of 
NOACs are treated with a reduced dose, outwith the label 
Figure 4. Efficacy and safety of apixaban vs rivaroxaban. A, Any thromboembolic events; (B) stroke; (C) major bleeding; and (D) intracra-
nial hemorrhage. CI indicates confidence interval.
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recommendations for this reduced dose treatment.31 In an 
analysis from the ORBIT-AF II (Outcomes Registry for Better 
Informed Treatment of Atrial Fibrillation phase II), 9.4% of 
patients were undertreated with reduced dose NOACs, with up 
to 11.8% of apixaban users prescribed with reduced dose, with 
reduced dose associated with increased rate of major adverse 
outcomes.31 Our data showed that even greater proportion of 
patients are treated with the reduced dose, and our results 
suggest that treating patients with apixaban reduced dose is 
associated with worse outcomes. The finding that reduced 
dose apixaban was found more effective than dabigatran was 
unexpected. There is relatively limited evidence on direct or 
indirect comparisons of various reduced dose NOACs, so 
these data have to be cautiously interpreted. Indeed, we should 
consider the real-world observational nature of reported stud-
ies, where residual confounding may still be evident. Also, 
patients prescribed low or reduced dose in RWS may be older 
and more fragile because of multiple comorbidities (or at 
least, perceived to be so).
Thus far, many RWS papers have been released about the 
use and comparisons of either NOACs versus warfarin or 1 
NOAC versus other NOAC.4,5 Carmo et al4 performed a meta-
analysis of dabigatran versus warfarin in RWS and found 
that dabigatran was associated with a lower risk of stroke 
and major bleeding. Although a lower ICH risk was seen, an 
increased risk for GIB was reported for dabigatran 150 mg.4 
In another meta-analysis of RWS focused on rivaroxaban, Bai 
et al5 reported that rivaroxaban compared with warfarin was 
associated with a significant reduction in thromboembolic 
events but with a similar risk for major bleeding and GIB. 
Rivaroxaban was found to be as effective as dabigatran for 
prevention of thromboembolic events but was associated with 
an increased risk of major bleeding.5
Our article extends prior meta-analyses in understanding the 
impact of apixaban in real-life clinical practice. Compared with 
warfarin, regular dose apixaban was associated with a margin-
ally improved effectiveness in reducing thromboembolic events 
even though overall the difference was nonsignificant and NNT 
indicated a higher number of subjects to be treated to avoid 1 
thromboembolic event and a similar NNT for stroke prevention; 
however, a better safety profile, consistent with other RWS with 
other NOACs, was evident. In addition, apixaban had a similar 
effectiveness but a substantially better safety profile than dabig-
atran and rivaroxaban. Reassuring data about NOACs as a valid 
alternative to vitamin K antagonists from RWS have also been 
reported recently for secondary stroke prevention.32
Thus far, all NOACs have been considered broadly similar 
in effectiveness, with some possible differences in safety. Our 
data, even though based on indirect comparisons, and there-
fore to be interpreted cautiously, suggest that in the context 
of currently available RWS evidence apixaban could possi-
bly represent the best alternative for OAC therapy, balancing 
effectiveness and safety for many patients with AF.
Limitations
Our study has various limitations. First, we could not account 
for quality of anticoagulation control, for the studies compar-
ing apixaban with warfarin, nor adherence or persistence to 
NOACs. Indeed, these aspects are highly relevant in determin-
ing clinical outcomes.33–35 Another limitation is the relatively 
shorter follow-up of apixaban-treated patients compared with 
other NOACs and differences in length of exposure need to 
be considered for such comparisons.36 In addition, several 
meta-analyses are based on studies with high heterogeneity 
as testified by large I2 values. Also, the reduced number of 
studies included in some of the secondary comparisons has to 
be taken in consideration when interpreting the overall results. 
Finally, being based on RWS, the presence of unaccountable 
confounders has to be taken under consideration when inter-
preting our results.
Figure 5. Number needed-to-treat comparison between real-world studies and ARISTOTLE trial. GIB indicates gastrointestinal bleeding; 
ICH, intracranial hemorrhage; RWS, real-world studies; and TE, thromboembolic events.
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Summary
In this systematic review and meta-analysis, the use of apixa-
ban in real-life is associated with an overall similar effective-
ness in reducing stroke and any thromboembolic events when 
compared with warfarin. A better safety profile was found 
for apixaban when compared with warfarin, dabigatran, and 
rivaroxaban.
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2 
SUPPLEMENTARY METHODS 
Bias Assessment 
All studies have been evaluated to assess the risk of bias, independently by two of 
the co-authors (MP and IR) according to recommendations of Agency for Healthcare 
Research and Quality (AHRQ)1. Evaluation was performed for the following bias 
categories: selection, performance, attrition, detection and reporting bias. Finally, an 
overall evaluation was performed. All studies have been categorised as low, 
moderate or high risk of bias. Publication bias was analysed for the main primary 
outcomes. 
 
Studies Selection and Data Extraction 
After search, all results have been screened by two co-authors independently (IR 
and GFR), with disagreement resolved by collegial discussion with a third co-author 
(MP). All articles retrieved from the search were evaluated according to titles, 
abstract and full-text evaluation, sequentially. Studies for which it was possible to 
clearly ascertain a relevant overlap of cohorts were evaluated according to time of 
data collection and/or year of publication. Accordingly, studies collected and/or 
published more recently were included in the analysis. 
 
Data were extracted independently by two of the co-authors (MP and IR) using a 
shared electronic data sheet. All data on sample size of apixaban and any 
comparator subgroups, number of major adverse events, incidence rates or 
measures of effect were collected. Study characteristics, age and thromboembolic 
risk were also collected when available. Where available, data on use of reduced 
dose for every NOAC were extracted. Stratified analyses were performed according 
to the dose used when the study provided outcomes accordingly. Doses were 
defined as "regular or any dose” when regular dose was explicitly reported or when 
was not possible to establish which dose was used; “reduced dose” was used when 
explicitly reported for apixaban 2.5 mg bid, dabigatran 110 mg bid and rivaroxaban 
15 mg od. 
 
Outcomes Definition 
Primary outcomes considered were stroke and/or any thromboembolic event, major 
bleeding and intracranial hemorrhage (ICH). Secondary outcomes considered where 
available were hemorrhagic stroke, gastrointestinal bleeding (GIB), any bleeding and 
all-cause death.  
 
Outcomes were defined according to the definition and categorisation used in the 
original studies. Specifically, stroke outcome was used for all ischemic or undefined 
stroke, based on the original data. All central and/or peripheral embolic events were 
considered as ‘any thromboembolic event’. Major bleeding, ICH, hemorrhagic stroke 
and GIB were defined only when they were unequivocally and undoubtedly defined 
as per the original study. ICH and hemorrhagic stroke were not considered as 
interchangeable and assigned according to the original study report and endpoint 
distinction. Otherwise, bleeding events were defined as “any bleeding”. 
 
Statistical Analysis 
All statistical analyses were undertaken using Review Manager (RevMan) version 
5.3 (The Cochrane Collaboration 2014, Nordic Cochrane Centre Copenhagen, 
Denmark). Outcomes from each study were pooled and compared using a fixed-
 
3 
effect or random-effect model according to the heterogeneity between all included 
studies. Treatment effect was reported as odds ratio (OR) and 95% confidence 
interval (CI). We decided to report OR instead of RR for comparability with other 
references and for consistency: we have repeatedly stratified our results and used 
different outcomes, and OR tend to vary less over strata than risk ratios. 
The I2-statistic was quantified to measure heterogeneity. When an I2 of >70%  was 
observed, the DerSimonian and Laird random-effects model was used; while Mantel-
Haenszel summaries were used otherwise. When there were no events in one group 
a pseudo-count of 0.5 was added to each cell. A sensitivity analysis, according to 
evaluated risk of bias, was performed for all the outcomes that reported a significant 
treatment effect. When necessary, the expected number of events was calculated 
using event rates, sample size and follow-up duration or by using subgroups sample 
size, hazard ratios (HR) and 95% CI. The latter was necessary for two studies which 
reported only HR, and given hazard rates were generally low we assumed RR and 
HR corresponded for that studies. Additionally, a sensitivity analysis removing those 
two studies led to the same conclusions reported. Absolute risk reduction (ARR) and 
the number-needed to treat (NNT) were calculated after pooling effect sizes for 
comparison between apixaban and warfarin. A p-value <0.05 was considered 
statistically significant.
 4 
SUPPLEMENTARY TABLES 
Table I: Risk of Bias Evaluation for Included Studies 
STUDY	 SELECTION	BIAS	 PERFORMANCE	
BIAS	
ATTRITION	BIAS	 DETECTION	BIAS	 REPORTING	BIAS	 OVERALL	BIAS	
Lee	 Moderate	 High	 Low	 Low	 High	 High	
Shiga	 Low	 Low	 Low	 Low	 Low	 Low	
Al-Khalili	 High	 Low	 Low	 Low	 Low	 Moderate	
Coleman	 Low	 Low	 Low	 Low	 Low	 Low	
Larsen	 High	 Low	 Low	 Low	 Low	 Moderate	
Lip	 Low	 Low		 Low	 Low	 Low	 Low	
Noseworthy	 Low	 Low	 Low	 Low	 Low	 Low	
Staerk	 Low	 Low	 Low	 Low	 Low	 Low	
Yao	 Moderate	 Low	 Low	 Low	 Low	 Low	
Abraham	 Low	 Low	 Low	 Low	 Low	 Low	
Altay	 High	 High	 High	 Low	 Moderate	 High	
Forslund	 Low	 Low	 Low	 Low	 Low	 Low	
Halvorsen	 Low	 Low	 Low	 Low	 Low	 Low	
Lamberts	 Low	 Low	 Low	 Low	 Low	 Low	
Li	 Low	 Low	 Low	 Low	 Low	 Low	
Nielsen		 High	 Moderate	 Low	 Low	 Low	 Moderate	
 5 
SUPPLEMENTARY FIGURES 
Figure I: Publication Bias in Main Primary Outcomes for Comparison between 
Apixaban and Warfarin 
Legend: OR= odds ratio; SE= size effect. 
 6 
Figure II: Publication Bias in Main Primary Outcomes for Comparison between 
Apixaban and Dabigatran 
Legend: OR= odds ratio; SE= size effect. 
 7 
Figure III: Publication Bias in Main Primary Outcomes for Comparison between 
Apixaban and Rivaroxaban 
Legend: OR= odds ratio; SE= size effect.  
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Figure IV: Comparison of Apixaban versus Warfarin in Hemorrhagic Stroke 
Occurrence 
Legend: CI= confidence interval. 
 
Figure V: Comparison of Apixaban versus Warfarin in Gastrointestinal Bleeding 
Occurrence 
Legend: CI= confidence interval. 
  
 9 
Figure VI: Comparison of Apixaban versus Warfarin in Any Bleeding Occurrence 
Legend: CI= confidence interval. 
 
Figure VII: Comparison of Apixaban versus Warfarin in All-Cause Death Occurrence 
Legend: CI= confidence interval. 
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Figure VIII: Comparison of Apixaban versus Dabigatran in Gastrointestinal Bleeding 
Occurrence 
Legend: CI= confidence interval. 
 
 
Figure IX: Comparison of Apixaban versus Dabigatran in Any Bleeding Occurrence 
Legend: CI= confidence interval. 
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Figure X: Comparison of Apixaban versus Dabigatran in All-Cause Death 
Occurrence 
Legend: CI= confidence interval. 
 
 
Figure XI: Comparison of Apixaban versus Rivaroxaban in Hemorrhagic Stroke 
Occurrence 
Legend: CI= confidence interval. 
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Figure XII: Comparison of Apixaban versus Rivaroxaban in Gastrointestinal 
Bleeding Occurrence 
Legend: CI= confidence interval. 
 
Figure XIII: Comparison of Apixaban versus Rivaroxaban in Any Bleeding 
Occurrence 
Legend: CI= confidence interval. 
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Figure XIV: Comparison of Apixaban versus Rivaroxaban in All-Cause Death 
Occurrence 
Legend: CI= confidence interval. 
 
Figure XV: Comparison of Apixaban versus Warfarin in Any Thromboembolic Event 
Occurrence Stratified According Risk of Bias 
Legend: CI= confidence interval. 
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Figure XVI: Comparison of Apixaban versus Rivaroxaban in Any Thromboembolic 
Event Occurrence Stratified According Risk of Bias 
Legend: CI= confidence interval. 
 
Figure XVII: Comparison of Apixaban versus Rivaroxaban in Stroke Occurrence 
Stratified According Risk of Bias 
Legend: CI= confidence interval.  
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